Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOsfoCipro: Fosfomycin vs ciprofloxacin as oral step-down for E. coli complicated UTI in women
2016-004486-37Phase 3Active
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fosfomycin in complicated urinary tract infection (cUTI), urinary tract infection (UTI) and colibacillosis (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Cumulative incidence of survival and clinical cure 6–10 days post-treatment. Started Aug 2017; status: active.
02
Drugs
fosfomycin
03
Conditions
complicated urinary tract infection (cUTI)urinary tract infection (UTI)colibacillosis
Beyond the preview
Go deeper on 2016-004486-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004486-37.